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Formation of glucosamine-6-phosphate (GlcN6P) by enzyme GlcN6P synthase (GlmS)
represents the first step in bacterial cell envelope synthesis. In Escherichia coli,
expression of glmS is controlled by small RNAs (sRNAs) GlmY and GlmZ. GlmZ
activates the glmS mRNA by base-pairing. When not required, GlmZ is bound by
adapter protein RapZ and recruited to cleavage by RNase E inactivating the sRNA. The
homologous sRNA GlmY activates glmS indirectly. When present at high levels, GlmY
sequesters RapZ by an RNA mimicry mechanism suppressing cleavage of GlmZ. The
interplay of both sRNAs is believed to adjust GlmS synthesis to the needs of the cell,
i.e., to achieve GlcN6P homeostasis. Bacilysin (tetaine) and Nva-FMDP are dipeptide
antibiotics that impair cell envelope synthesis by inhibition of enzyme GlmS through
covalent modification. However, although taken up efficiently, these antibiotics are less
active against E. coli for reasons unknown so far. Here we show that the GlmY/GlmZ
circuit provides resistance. Inhibition of GlmS causes GlcN6P deprivation leading to
activation of GlmY and GlmZ, which in turn trigger glmS overexpression in a dosage-
dependent manner. Mutation of glmY or glmZ disables this response and renders the
bacteria highly susceptible to GlmS inhibitors. Thus, E. coli compensates inhibition of
GlmS by increasing its synthesis through the GlmY/GlmZ pathway. This mechanism
is also operative in Salmonella indicating that it is conserved in Enterobacteriaceae
possessing these sRNAs. As GlmY apparently responds to GlcN6P, co-application of
a non-metabolizable GlcN6P analog may prevent activation of the sRNAs and thereby
increase the bactericidal activity of GlmS inhibitors against wild-type bacteria. Initial
experiments using glucosamine-6-sulfate support this possibility. Thus, GlcN6P analogs
might be considered for co-application with GlmS inhibitors in combined therapy to treat
infections caused by pathogenic Enterobacteriaceae.
Keywords: glucosamine-6-phosphate synthase GlmS, Nva-FMDP, Bacilysin, intrinsic resistance, small RNA,
GlmY, GlmZ, antimicrobial chemotherapy
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INTRODUCTION
The continuous increase and spread of antibiotic resistance
mechanisms among bacterial pathogens represents a major threat
for public health. Of particular concern is the recent emergence
of extended spectrum β-lactamases and carbapenemases in
pathogenic Enterobacteriaceae limiting therapeutic treatment
options for infections caused by these bacteria. Thus, there is
an urgent need for novel therapies, which may not only include
the discovery of novel antibacterial drugs, but also revision
of known compounds that were previously neglected (Brown
and Wright, 2016; Mühlen and Dersch, 2016). Many clinically
relevant antibiotics interfere with the biochemical machinery
for peptidoglycan biosynthesis (Silver, 2013; Borisova et al.,
2014). However, the initial steps in this pathway collectively
referred to as hexosamine pathway, have been rarely considered
as drug targets. The hexosamine pathway generates UDP–
N-acetyl-glucosamine (UDP–GlcNAc) and is initiated by key
enzyme glucosamine-6-phosphate (GlcN6P) synthase GlmS,
which synthesizes GlcN6P from L-glutamine and fructose-6-
phosphate (Figure 1A; Milewski, 2002; Teplyakov et al., 2002).
GlmS is essential unless exogenous amino sugars such as
glucosamine (GlcN) are available in adequate amounts. GlcN
can be taken up and converted to GlcN6P, thereby bypassing
GlmS (Figure 1A) (Plumbridge, 2015). The GlcN concentration
in human bodily fluids is too low to sustain growth of glmS
mutants making GlmS essential for enteric bacteria colonizing
the human host (Persiani et al., 2007; Kim et al., 2013; Bennett
et al., 2016).
Several naturally produced antibiotics that inhibit GlmS
enzymatic activity have been identified including bacilysin
and compound A 19009 synthesized by Bacillus subtilis and
Streptomyces collinus, respectively (Molloy et al., 1972; Kenig
and Abraham, 1976). These antibiotics are dipeptides of exotic
amino acids and rely on peptide transporters for uptake
and on intracellular peptidases for release of the warhead
moiety, which is anticapsin in case of bacilysin (Figures 1A,B;
Milewski, 2002; Özcengiz and Ögülür, 2015). A systematic
survey of synthetic derivatives related to A 19009 identified
the corresponding methylester N3-(4-methoxyfumaroyl)-(S)-
2,3-diaminopropanionic acid (FMDP) as most efficient and
selective inhibitor of purified GlmS from various organisms
including Escherichia coli and Salmonella (Chmara et al., 1986;
Badet et al., 1988). Among various tested FMDP peptides,
L-norvalyl-FMDP (Nva-FMDP; Figures 1A,B) exhibited the
strongest growth inhibitory effect on bacteria (Andruszkiewicz
et al., 1987; Chmara et al., 1998). FMDP as well as anticapsin act as
glutamine analogs and covalently bind to the glutamine binding
domain of GlmS causing its irreversible inhibition (Milewski
et al., 1986; Kucharczyk et al., 1990). As a result, GlcN6P
production is blocked leading to exhaustion of nucleotide
precursors for peptidoglycan biosynthesis and ultimately to
bacteriolysis. Cell death can be prevented by co-administration
of amino sugars demonstrating that these antibiotics are specific
for GlmS and lack off-target activity (Kenig and Abraham, 1976;
Chmara et al., 1998). Nva-FMDP is highly effective against
Gram-positive bacteria, but shows only weak activity against
FIGURE 1 | Role, regulation and inhibitors of enzyme GlmS in
Escherichia coli. (A) Key role of enzyme GlmS in the hexosamine pathway
and its inhibition by antibiotics. GlmS catalyzes synthesis of GlcN6P from
fructose-6-phosphate and glutamine. When available, amino sugars such as
GlcN can be taken up and converted to GlcN6P bypassing the need for GlmS.
GlcN6P is further converted by enzymes GlmM and GlmU to UDP-GlcNAc,
which is the last common precursor for synthesis of peptidoglycan and
lipopolysaccharides (LPS). The dipeptide antibiotics Nva-FMDP and bacilysin
require peptide transporters such as Dpp for uptake. Intracellular hydrolysis
releases the active C-terminal moieties FMDP and anticapsin, which inhibit
GlmS through covalent binding to a residue in the glutamine binding pocket.
(B) Structures of the dipeptide antibiotics bacilysin and Nva-FMDP.
(C) Feedback regulation of GlmS synthesis by small RNAs GlmY and GlmZ
and adapter protein RapZ in E. coli (Göpel et al., 2013, 2016). GlmZ
base-pairs with the glmS 5′-UTR enhancing translation and stabilizing the
transcript. Alternatively, GlmZ is bound by adapter protein RapZ and recruited
to cleavage by RNase E. The decision on the fate of GlmZ is made by the
homologous decoy sRNA GlmY. Upon GlcN6P scarcity, GlmY accumulates
and sequesters RapZ thereby counteracting cleavage of GlmZ by RNase E.
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E. coli [minimal inhibitory concentration (MIC) ≥ 100 µg/ml;
Andruszkiewicz et al., 1987; Chmara et al., 1998], although
it is taken up rapidly and efficiently by the Dpp dipeptide
ATP binding cassette (ABC) transporter (Marshall et al.,
2003). So far, the reason for this weak efficacy remained
mysterious.
Synthesis of GlmS is feed-back regulated by GlcN6P, thereby
achieving homeostasis of this metabolite. The underlying
mechanisms employ regulatory RNA elements, but differ
remarkably between Gram-positive and Gram-negative bacteria.
The glmS mRNA of Gram-positive species contains a ribozyme
in its 5′-untranslated region (5′-UTR), which upon binding
of GlcN6P triggers self-cleavage leading to down-regulation
of glmS expression (Winkler et al., 2004). In contrast,
E. coli and presumably most species of the Gram-negative
Enterobacteriaceae employ two trans-encoded homologous small
RNAs (sRNAs), GlmY and GlmZ, and adapter protein RapZ
to regulate GlmS synthesis (Figure 1C) (Reichenbach et al.,
2008; Urban and Vogel, 2008; Göpel et al., 2013, 2016). Assisted
by RNA chaperone Hfq, GlmZ base-pairs with the 5′-UTR of
the glmS transcript and stimulates translation concomitantly
stabilizing the mRNA. In an alternative fate, GlmZ is bound by
protein RapZ, which recruits RNase E to inactivate the sRNA
through processing. The path to be taken by GlmZ is ultimately
determined by the level of sRNA GlmY. GlmY accumulates
when GlcN6P decreases in the cell and sequesters RapZ through
molecular mimicry. As a result, GlmZ remains un-cleaved and
upregulates glmS expression to replenish GlcN6P. In addition,
in enterohemorrhagic E. coli GlmY and GlmZ were recruited
to regulate horizontally acquired virulence genes (Gruber and
Sperandio, 2014, 2015).
In the present study, we investigated the roles of GlmY
and GlmZ for susceptibility to GlmS inhibitors. We show
that these sRNAs provide intrinsic resistance by countervailing
inhibition of GlmS with its increased synthesis. Beyond E. coli,
this mechanism also operates in Salmonella indicating that
it applies to a wider range of enterobacterial species in
which these sRNAs are conserved. Our findings indicate
that compounds suppressing GlmY and/or GlmZ would
increase the efficacy of GlmS inhibitors when applied in
combination. Experiments using the non-metabolizable GlcN6P
analog glucosamine-6-sulfate (GlcN6SO4) are in favor of this
possibility.
MATERIALS AND METHODS
Bacterial Strains, Culture Conditions,
and Chemicals
Bacterial strains used in this study are listed in Table 1.
Derivatives of E. coli MG1655 were used to test the bacteriocidal
effects of Nva-FMDP and bacilysin. In these strains the lacZ gene
is deleted allowing monitoring of lacZ reporter gene fusions.
General transduction by phage T4GT7 (Wilson et al., 1979)
was used to introduce established 1glmY::cat, 1glmZ::cat alleles
and the spectinomycin resistance tagged glmS’–lacZ fusion into
strain S4197, respectively. The temperature-sensitive Flippase
(FLP)-recombinase plasmid pCP20 was used to remove the
chloramphenicol resistance genes (Datsenko and Wanner,
2000). Additional experiments were performed using Salmonella
enterica serovar Typhimurium strain SL1344 and its 1glmY and
1glmZ derivatives JVS112 and JVS122, respectively (Papenfort
et al., 2008). Bacteria were grown at 37◦C in Luria-Bertani
(LB) Lennox, Mueller Hinton broth (Merck), MacConkey
lactose (Roth), and M9 minimal medium (Miller, 1972). M9
medium was supplemented with 1% [w/v] glucose as carbon
source and in case of Salmonella strains additionally with
0.002% L-histidine. Antibiotics were added when required:
chloramphenicol (15 µg/ml), spectinomycin (75 µg/ml),
neomycin (4 µg/ml), erythromycin (0.5 µg/ml). Nva-FMDP
was synthesized as described previously (Andruszkiewicz
et al., 1987) and solved in H2O to yield a stock solution
of 1 mg/ml. D-GlcN6SO4 was purchased from Santa Cruz
Biotechnology. B. subtilis strain TI304, which overproduces
bacilysin, was used to prepare bacilysin enriched culture
supernatant as previously described (Inaoka et al., 2009).
Bacilysin-free supernatant, which served as negative control,
was prepared using B. subtilis strain TI398. The latter strain is
unable to synthesize bacilysin due to inactivation of gene ywfE
(bacD) encoding alanine–anticapsin ligase (Inaoka et al., 2009).
The culture supernatants were concentrated 20-fold using a
centrifugal evaporator and subsequently stored at −20◦C until
further use.
Large Scale Liquid Culture Experiments
to Study the Effects of Nva-FMDP and
Bacilysin
Large scale cultures were grown to assess the effect of Nva-
FMDP and Bacilysin on cell viability and the regulatory
GlmY/GlmZ/glmS circuit. To test Nva-FMDP, strains were
inoculated from overnight cultures in 35 ml LB medium
to an OD600 ∼ 0.1 and grown until an OD600 ∼ 0.3.
Subsequently, cultures were split into three 10 ml subcultures
that were supplemented either with 100 µg/ml Nva-FMDP,
100 µg/ml Nva-FMDP + 0.2% GlcN or with the equivalent
volume of H2O (mock control), respectively. Growth was
continued for 6 h and 1.5 ml samples were taken in hourly
intervals for RNA extraction and to determine the OD600,
CFU numbers and β-galactosidase activities. A similar setup
was used to test bacilysin-containing culture supernatant but
as a difference cultures were split at an OD600 ∼ 0.2
and supplemented either with 1.5 ml concentrated culture
supernatant of B. subtilis strains TI304 or TI398 or with H2O
(mock control), respectively.
Determination of CFU Numbers
To determine CFU numbers, serial dilutions of the cultures
were prepared in Mg saline (145 mM NaCl, 10 mM
MgSO4) and appropriate dilutions were plated in duplicate
on non-selective LB agar. Following incubation at 37◦C
overnight, colonies were counted from plates containing
30–300 colonies using a Stuart SC6 colony counter (Bibby
Scientific).
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TABLE 1 | Bacterial strains used in this study.
Name Genotype Reference/construction
Bacillus subtilis
TI304 168 1scoC::spc, abrB::neo, codY::erm (Inaoka et al., 2009)
TI398 168 ywfA::neo, ywfE179 (Inaoka et al., 2009)
Escherichia coli
S4197 MG1655 rph+, ilvG+, 1lacZ (Venkatesh et al., 2010)
Z8 CSH50 1(pho-bgl)201, 1(lac-pro), ara, thi,
λattB::[aadA (specR), glmS -5′::lacZ], strpR, F’(lacIq)
(Kalamorz et al., 2007)
Z44 CSH50 1(pho-bgl)201, 1(lac-pro), ara, thi, 1glmZ::cat (Kalamorz et al., 2007)
Z95 CSH50 1(pho-bgl)201, 1(lac-pro), ara, thi, 1glmY::cat (Reichenbach et al., 2008)
Z834 S4197 1glmY::cat T4GT7 (Z95)→ S4197; this work
Z835 S4197 1glmZ::cat T4GT7 (Z44)→ S4197; this work
Z838 S4197 1glmY Z834 cured from cat; this work
Z839 S4197 1glmZ Z835 cured from cat; this work
Z854 S4197 λattB::[aadA (specR), glmS -5′::lacZ] T4GT7 (Z8)→ S4197; this work
Z855 S4197 λattB::[aadA (specR), glmS -5′::lacZ], 1glmY T4GT7 (Z8)→ Z838; this work
Z856 S4197 λattB::[aadA (specR), glmS -5′::lacZ], 1glmZ T4GT7 (Z8)→ Z839; this work
Salmonella enterica serovar Typhimurium
SL1344 StrR, his, rpsL, xyl (Hoiseth and Stocker, 1981)
JVS112 SL1344 1glmY (Papenfort et al., 2008)
JVS122 SL1344 1glmZ (Papenfort et al., 2008)
Extraction of Total RNA and Northern
Blotting
Total RNA was extracted from 1 ml samples using the
RNeasy mini kit (Qiagen) according to the instructions of
the manufacturer. The RNAs of interest were detected in
subsequent Northern experiments using DIG labeled RNA
probes that were generated by in vitro transcription using the
DIG labeling kit (Roche diagnostics). The corresponding DNA
templates were obtained by PCR using previously described
oligonucleotide primers (Reichenbach et al., 2008, 2009). To
detect sRNAs GlmY and GlmZ, 2.5 µg total RNA per lane
were separated on 8% polyacrylamide gels containing 7 M urea
and 1 × TBE. Subsequently, RNA was transferred to a nylon
membrane (Hybond N+, GE healthcare) by electro-blotting and
cross-linked by 254 nm UV radiation. RNA hybridization and
detection was performed according the supplier’s instruction
(Roche Diagnostics). To obtain 5S loading controls, sRNA probes
were stripped by incubating the membrane 2× for 60 min in
50% formamide, 5% SDS, 50 mM Tris-HCl pH 7.5. Subsequently,
the membrane was re-probed using a probe directed against the
rrfD transcript. For detection of glmS mRNA, 5 µg total RNA per
lane were separated by formaldehyde agarose gel electrophoresis
(1% agarose, 18% formaldehyde, 20 mM MOPS, 5 mM sodium
acetate, 1 mM EDTA, pH 7.0) and subsequently blotted onto a
Hybond N+ nylon membrane using the VacuGene XL vacuum
blotting system (Amersham Biosciences) at 80 mbar for 4 h. To
obtain loading controls, the 23S and 16S rRNAs were visualized
by ethidium bromide prior to blotting.
β-Galactosidase Assays
β-Galactosidase enzyme activities were determined as described
previously (Miller, 1972). Enzyme activities are expressed
in Miller units and represent the average of at least two
measurements using independent cultures.
Disk Diffusion Assay
Disk diffusion assays (Bauer et al., 1966) were carried out
on various media including Mueller Hinton, LB Lennox,
MacConkey lactose and M9 agar. Cells were grown at 37◦C in
LB to an OD600 ∼ 0.5, pelleted and re-suspended in the medium
subsequently used in the assay. A volume containing ∼4 × 107
cells was mixed with 4 ml thin agar layer (medium containing
7.5% agarose) that was kept molten at 44◦C and subsequently
spread over 15 ml solid agar base of the same medium prepared in
100 mm Petri dishes. The compounds to be tested were adsorbed
onto 6 mm cellulose disks (Rotilabo), which were subsequently
placed on the seeded agar surface in the Petri dishes. Growth
inhibition zones were recorded following incubation for 16 h at
37◦C. Assays were performed at least twice using independent
cultures.
Determination of MICs
Minimal inhibitory concentrations were determined in various
media according the guidelines of the European society
of clinical microbiology and infectious diseases using the
broth microdilution method (EUCAST, 2003). Briefly, serial
dilutions of the compounds to be tested were prepared in
96 well plates (Sterilin) and subsequently inoculated with
5 × 105 CFU/ml of an overnight culture grown in the same
medium as used for MIC determination. Following incubation
at 37◦C for 12 h growth was monitored spectrophotometrically
by measuring the OD595 using a microplate reader (iMark
plate reader, BioRad). MIC was defined by the lowest drug
concentration preventing visible growth (OD595 < 0.1). MIC
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assays were performed at least twice using independent
cultures.
RESULTS
Escherichia coli Responds to Nva-FMDP
by Overexpression of glmS
Nva-FMDP exerts only a moderate growth inhibitory effect on
E. coli cells (Andruszkiewicz et al., 1987). Our preliminary results
suggested that E. coli responds to this drug by upregulation
of GlmS synthesis (Reichenbach et al., 2008). To gain further
insight, we first studied the effect of Nva-FMDP at sub-MIC
concentrations. To this end, we used strain Z854, a derivative
of E. coli K-12 reference strain MG1655 carrying an ectopic
glmS’–lacZ fusion on the chromosome. Strain Z854 was grown in
LB Lennox supplemented with either 100 µg/ml Nva-FMDP, or
100 µg/ml Nva-FMDP + 0.2% GlcN or with the corresponding
volume of water (mock control). OD600 readings detected
no growth impairment by Nva-FMDP (Supplementary Figure
S1A). However, the CFU number was diminished ∼twofold
as compared to the mock control (Figure 2A). Addition of
GlcN cured this growth defect, corroborating that Nva-FMDP
causes cell death by depletion of intracellular GlcN6P resulting
from GlmS inhibition. To determine glmS expression levels,
total RNA was extracted from cells harvested during the first
3 h of growth and analyzed by Northern blotting. In parallel,
the β-galactosidase activities were determined. Both assays
consistently detected a strong upregulation of glmS expression
in the Nva-FMDP treated cells, which was suppressed by
the addition of GlcN (Figures 2B, bottom panel and 4B,
columns left). To determine whether GlmY and GlmZ are
involved in upregulation of glmS expression in response to
Nva-FMDP, we performed Northern blotting. Indeed, high
levels of GlmY and of full-length GlmZ were observed in
the Nva-FMDP treated cells but not in the other samples
(Figure 2B).
Activation of the GlmY/GlmZ/glmS
Regulatory Cascade Is Not Restricted to
Nva-FMDP But Applies to GlmS
Inhibitors in General
Next, we determined whether upregulation of the
GlmY/GlmZ/glmS regulatory cascade is specific to Nva-
FMDP or may also apply to other GlmS inhibitors such as
bacilysin. Since bacilysin is commercially unavailable, we used
concentrated culture supernatant of B. subtilis strain TI304,
which overproduces and secretes bacilysin into the medium
(Inaoka et al., 2009). Culture supernatant of the bacilysin-
negative B. subtilis mutant TI398 served as negative control.
E. coli strain Z854 was grown in LB Lennox supplemented
with supernatant of B. subtilis strain TI304 or TI398 or with
water (mock control). Presence of the bacilysin containing
supernatant resulted in slight growth retardation, which was
not observable in the culture treated with supernatant of
the bacilysin-negative mutant (Figure 3A). This observation
FIGURE 2 | Nva-FMDP triggers accumulation of GlmY, GlmZ and glmS
RNAs in E. coli and co-administration of GlcN suppresses this effect.
(A) CFU numbers of cultures of E. coli strain Z854 grown in LB supplemented
either with 100 µg/ml Nva-FMDP (diamonds) or 100 µg/ml Nva-FMDP +
0.2% glucosamine (triangles) or the equivalent volume of H2O (mock control;
squares). The corresponding OD600 readings are provided in Supplementary
Figure S1A. (B) Northern analysis of GlmY, GlmZ, and glmS RNAs in the
cultures analyzed in (A). Total RNA was extracted from samples harvested at
hourly intervals during the first 3 h after inoculation and subsequently probed
for GlmY (top panel), GlmZ (medium panel) and glmS RNAs (bottom panel).
Loading controls are provided in Supplementary Figure S1B. The various RNA
species are indicated by arrows. Processed variants are denoted by asterisks.
indicated that the growth defect was specifically caused by
bacilysin present in the culture supernatant of TI304. Northern
blot analysis of RNA extracted from samples harvested at various
times detected accumulation of the glmS transcript and of the
GlmY/GlmZ sRNAs in cells treated with supernatant of TI304,
similar to cells treated with Nva-FMDP, which was tested in
parallel (Figure 3B). Upregulation of glmS in response to the
bacilysin-containing culture supernatant was also confirmed by
β-galactosidase assays (Figure 3C, columns left). In contrast,
the culture supernatant of strain TI398 had no effect on GlmY,
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FIGURE 3 | Bacilysin causes accumulation of GlmY, GlmZ and glmS RNAs in E. coli recapitulating the effects of Nva-FMDP. E. coli strains Z854
(wild-type), Z855 (1glmY ) and Z856 (1glmZ) were grown in LB supplemented either with culture supernatant (SN) of B. subtilis strain TI304 overproducing bacilysin
or with SN derived from the bacilysin-negative B. subtilis mutant TI398. Cultures treated with the equivalent volume of H2O served as mock control. (A) Growth
curves of the various cultures as determined by OD600 recording. (B) Northern blot analysis for detection of GlmY, GlmZ and glmS in the cultures of E. coli wild-type
strain Z854. Samples for isolation of total RNA were harvested 1, 3, and 5 h after inoculation of the cultures. For comparison, a culture of strain Z854 treated with
Nva-FMDP was analyzed in parallel. Loading controls are provided in Supplementary Figure S2. It should be noted that expression of glmY is generally upregulated
in E. coli when entering the stationary phase (Göpel et al., 2013) explaining accumulation of GlmY in the mock control culture following 5 h of growth. However, the
high GlmY levels are not transduced to glmS due to the low expression levels of GlmZ under these conditions. (C) β-Galactosidase assays monitoring expression of
a glmS’–lacZ reporter fusion in the various cultures. Enzyme activities were determined from samples harvested after 1, 3, and 5 h of growth.
GlmZ, and glmS as judged from comparison with the mock
control (Figures 3B,C). Taken together, the data indicate that
activation of the GlmY/GlmZ system and overexpression of glmS
is not a specific response to Nva-FMDP but applies to GlmS
inhibitors in general.
E. coli Mutants Lacking GlmY or GlmZ
Fail to Upregulate glmS in Response to
GlmS Inhibitors
Northern analyses showed that Nva-FMDP and bacilysin trigger
accumulation of sRNAs GlmY and GlmZ concomitantly with
the glmS mRNA and additional presence of GlcN suppressed
this effect (Figures 2B and 3B). This observation suggested that
intracellular depletion of GlcN6P caused by GlmS inhibition
led to activation of the GlmY/GlmZ sRNAs, which in turn
stimulated glmS expression. To prove this hypothesis, we studied
the effect of Nva-FMDP on isogenic E. coli 1glmY and 1glmZ
mutants, respectively. The strains were grown in the absence or
presence of 100 µg/ml Nva-FMDP and samples were harvested
at hourly intervals and analyzed. Northern blot analysis as well
as determination of β-galactosidase activities revealed that both
mutants failed to activate glmS expression in response to Nva-
FMDP, whereas glmS strongly accumulated in the wild-type
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strain as observed before (Figures 4B,C). In the 1glmY mutant
treated with Nva-FMDP, stabilization of the full-length variant
of GlmZ did not occur, explaining the inability to activate glmS
(Figure 4C, middle). Vice versa, GlmY still accumulated in the
1glmZ mutant upon exposure to Nva-FMDP, but remained
without effect on glmS, which is explained by the absence of
GlmZ (Figure 4C, right). As judged from glmS’–lacZ fusion data,
the 1glmY and 1glmZ mutants also failed to activate glmS in
response to bacilysin (Figure 3C). Therefore, these data show
that antibiotics inhibiting GlmS induce glmS overexpression
through activation of the GlmY/GlmZ regulatory sRNA cascade.
Interestingly, growth monitoring suggested that both sRNA
mutants are more susceptible to growth inhibition by Nva-FMDP
and bacilysin as compared to the wild-type (Figures 3A and 4A).
Mutation of GlmY or GlmZ Attenuates
Intrinsic Resistance of E. coli to
Nva-FMDP
To investigate the possibly higher sensitivity of 1glmY and
1glmZ mutants to GlmS inhibitors, we first studied the effect
of Nva-FMDP more thoroughly using the broth microdilution
FIGURE 4 | Escherichia coli mutants lacking GlmY or GlmZ do not respond to Nva-FMDP by upregulation of glmS mRNA levels. E. coli strains Z854
(wild-type), Z855 (1glmY ) and Z856 (1glmZ) were grown in LB supplemented either with Nva-FMDP or the equivalent volume of water (mock control), respectively.
(A) CFU numbers of the various cultures. (B) β-Galactosidase assays monitoring expression of a glmS’–lacZ reporter fusion in the various cultures during the first
3 h following inoculation. (C) Northern analysis for detection of GlmY, GlmZ and glmS RNAs in the various cultures. For details, see legend of Figure 2B. Loading
controls are provided in Supplementary Figure S3.
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method. Serial dilutions of Nva-FMDP in LB medium were
inoculated with the wild-type strain and the 1glmY and
1glmZ mutants, respectively. Following 12 h incubation,
the OD595 of the cultures and the β-galactosidase activities
were determined. Growth of the wild-type strain was slightly
impaired only at highest Nva-FMDP concentrations (Figure 5A;
MIC > 500 µg/ml). In contrast, growth of the mutant strains
was completely inhibited at Nva-FMDP concentrations above
62.5 µg/ml. This higher susceptibility of the mutants can
be attributed to the incapability to increase glmS expression
as indicated by constantly low glmS’–lacZ expression levels
regardless of the applied Nva-FMDP concentration (Figure 5B).
In contrast, the wild-type strain exhibited glmS’–lacZ expression
levels that gradually increased with incremental Nva-FMDP
concentrations (Figure 5B). Thus, GlmY and GlmZ enable E. coli
to activate glmS expression in a dosage-dependent manner,
thereby overcoming inhibition of GlmS enzymatic activity by
Nva-FMDP.
Next, we characterized susceptibility of the various E. coli
strains to Nva-FMDP more systematically. To this end, we
performed disk diffusion assays and MIC determinations in
various media (Tables 2 and 3; Supplementary Figures S4A,B).
Nva-FMDP showed no significant activity against the wild-
type strain when grown in LB or Mueller Hinton medium.
However, reasonable activity was detectable when the bacteria
grew in MacConkey or M9 minimal medium, indicating that the
antibacterial activity of Nva-FMDP is modulated by composition
of the growth medium. In contrast to the wild-type, the 1glmY
and 1glmZ mutants were growth-inhibited by Nva-FMDP in
all media. Larger inhibition zones as compared to the wild-type
were observed on the various disk diffusion plates and MIC
values of the mutants were roughly fourfold lower demonstrating
that absence of GlmY or GlmZ increases susceptibility to Nva-
FMDP significantly (Tables 2 and 3, Supplementary Figure
S4A,B). Again, susceptibility of the mutants to Nva-FMDP
varied with the growth medium increasing in the order Mueller
Hinton < LB < MacConkey lactose < M9 minimal medium.
Co-administration of GlcN abolished growth inhibition by Nva-
FMDP on the disk diffusion plates, regardless whether GlcN was
included in the growth medium or directly administered on the
filter disk (Supplementary Figures S4B,D), re-emphasizing that
Nva-FMDP acts via depletion of metabolites of the amino sugar
pathway.
The Mechanism of Intrinsic Resistance
to GlmS Inhibitors Procured by GlmY and
GlmZ Is Also Operative in Salmonella
GlmY and GlmZ are conserved in Enterobacteriaceae and
sequence analysis suggests that this even applies to GlmZ/glmS
base-pairing (Fröhlich and Vogel, 2009; Göpel et al., 2011).
This raises the possibility that GlmY and GlmZ may also
bestow other Enterobacteriaceae with intrinsic resistance to
GlmS inhibitors. To test this hypothesis, we investigated the
effect of Nva-FMDP on the virulent Salmonella enterica serovar
Typhimurium strain SL1344 and its isogenic 1glmY and 1glmZ
mutants. First, we repeated the experiment shown in Figure 2,
FIGURE 5 | GlmY and GlmZ enable E. coli to resist the bactericidal
effect of Nva-FMDP by upregulation of glmS expression in a
dosage-dependent manner. Serial dilutions of Nva-FMDP in LB medium
were inoculated with 5 × 105 CFU/ml of E. coli strains Z854 (wild-type), Z855
(1glmY ) and Z856 (1glmZ), respectively. (A) Cell densities of the cultures as
determined by OD595 measurements after 12 h incubation.
(B) β-Galactosidase activities monitoring expression of a chromosomal
glmS’–lacZ fusion in the various cultures.
but used the Salmonella wild-type strain rather than E. coli.
Indeed, Nva-FMDP elicited concomitant accumulation of GlmY
and of the full-length variant of GlmZ (Figure 6B, top and
medium panel). As expected, this resulted in upregulation
of glmS mRNA (Figure 6B, bottom panel). The additional
presence of GlcN suppressed accumulation of the various
RNAs, recapitulating the observations in E. coli (compare
Figures 2B and 6B). Nva-FMDP had a significant negative
effect on the viable cell number (Figure 6A), although this
was not reflected by the OD600 readings (Supplementary Figure
S5A), as observed for E. coli (Figure 2A; Supplementary
Figure S1A).
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TABLE 2 | Disk diffusion assays addressing susceptibility of Escherichia coli and Salmonella strains to Nva-FMDP on various media.
Escherichia coli K12 Salmonella enterica serovar Typhimurium
Potency Nva-FMDP [µg] Wild-type (Z854) 1glmY (Z855) 1glmZ (Z856) Wild-type (SL1344) 1glmY (JVS112) 1glmZ (JVS122)
LB Lennox
100 − 24 ± 1 24 ± 1 10 ± 1 18 ± 1 22 ± 0
20 − 20 ± 1 19 ± 4 − 12 ± 0 15 ± 0
10 − 14 ± 1 13 ± 1 − 9 ± 0 9 ± 0
Mueller Hinton
100 − 10 ± 1 12 ± 1 10 ± 0 15 ± 0 16 ± 0
20 − − 9 ± 1 − 12 ± 1 13 ± 0
10 − − − − 9 ± 1 11 ± 0
MacConkey, lactose
100 13 ± 1 27 ± 1 27 ± 1 21 ± 1 27 ± 0 30 ± 0
20 − 23 ± 1 22 ± 1 17 ± 1 23 ± 1 26 ± 1
10 − 19 ± 1 19 ± 2 13 ± 0 21 ± 1 23 ± 0
M9 glucose
5 13 ± 1 19 ± 1 22 ± 2 14 ± 4 19 ± 1 24 ± 0
2 9 ± 1 15 ± 1 20 ± 3 13 ± 0 16 ± 2 22 ± 0
1 − 13 ± 1 19 ± 4 11 ± 1 13 ± 2 20 ± 0
Diameters of zones of growth inhibition (mm) are recorded.
TABLE 3 | Susceptibility [minimal inhibitory concentration (MIC) in µg/ml] of E. coli and Salmonella strains to Nva-FMDP in various growth media.
Escherichia coli K12 Salmonella enterica serovar Typhimurium
Medium Wild-type (Z854) 1glmY (Z855) 1glmZ (Z856) Wild-type (SL1344) 1glmY (JVS112) 1glmZ (JVS122)
LB Lennox >500 125 125 500 31.3 7.8
Mueller Hinton >500 >500 >500 125 25 6.25
MacConkey, lac 6.25 1.56 0.78 3.13 0.39 0.2
M9 glucose 0.16 0.04 0.08 0.31 0.08 0.01
Next, we studied susceptibility of Salmonella to Nva-
FMDP and the roles of sRNAs GlmY and GlmZ in
this process by carrying out disk diffusion assays and
MIC determinations using wild-type strain SL1344 as
well as the sRNA deletion strains (Tables 2 and 3;
Supplementary Figures S4A,C). Globally, the results
resembled those obtained for E. coli, but with some
remarkable differences. First, Nva-FMDP had a stronger
growth inhibitory effect on the Salmonella wild-type strain
as compared to the E. coli wild-type. Zones of growth
inhibition could be detected in all media (Table 2) and
MIC values were generally lower for Salmonella decreasing
in the order LB > Mueller Hinton > MacConkey
lactose > M9 glucose (Table 3). Second, the absence
of GlmY and GlmZ strongly increased susceptibility
to Nva-FMDP confirming that these sRNAs provide
intrinsic resistance even in Salmonella. Apparently, the
sRNAs had a stronger impact on drug susceptibility in
Salmonella: Depending on the medium, mutation of
GlmY decreased the MIC 4- to 15-fold and mutation
of GlmZ even 16- to 64-fold, whereas in E. coli a ∼4-
fold effect was seen (Table 3). In conclusion, GlmY
and GlmZ are key players for the intrinsic resistance to
antibiotics inhibiting GlmS, not only in E. coli but also in
Salmonella.
Combination with a Non-metabolizable
GlcN6P Analog May Increase Efficacy of
Nva-FMDP against the E. coli Wild-Type
As GlmY and GlmZ are crucial for overcoming the deleterious
effect of GlmS inhibitors, we reasoned whether suppression of
the sRNAs could increase efficacy of these drugs against wild-
type strains. Since the GlmY/GlmZ system apparently senses and
responds to intracellular GlcN6P levels, we considered that a non-
metabolizable analog of GlcN6P could potentially prevent the
GlmY/GlmZ-mediated upregulation of GlmS, thereby increasing
the efficacy of GlmS inhibition by Nva-FMDP. To provide a proof
of concept, we used GlcN6SO4, which was shown to activate
the B. subtilis glmS ribozyme to some extent in vitro indicating
that it may act as GlcN6P analog in biological systems (Winkler
et al., 2004). First, we tested GlcN6SO4 using disk diffusion
assays. A small inhibition zone of∼8 mm diameter was observed
when a filter disk loaded with 50 µg Nva-FMDP was applied
onto a MacConkey lactose plate seeded with the E. coli wild-
type strain Z854. Interestingly, the zone of growth inhibition
gradually increased up to 13 mm upon co-administration of
incremental amounts of GlcN6SO4 (Figure 7A). GlcN6SO4
showed no growth inhibitory properties on its own, indicating
that it acts specifically by enhancing the antibacterial potential
of Nva-FMDP (Supplementary Figure S6). Interestingly, this
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FIGURE 6 | Upregulation of GlmY, GlmZ, and glmS RNAs by Nva-FMDP
also occurs in Salmonella. (A) CFU numbers of cultures of Salmonella
strain SL1344 grown in LB containing either 100 µg/ml Nva-FMDP
(diamonds) or 100 µg/ml Nva-FMDP + 0.2% GlcN (triangles) or the equivalent
volume of H2O (mock control; squares). The corresponding OD600 readings
are provided in Supplementary Figure S5A. (B) Northern analysis of GlmY,
GlmZ and glmS RNAs in the cultures analyzed in (A). Total RNA was extracted
from samples harvested in hourly intervals during the first 3 h after inoculation
and subsequently probed for detection of GlmY (top panel), GlmZ (medium
panel) and glmS RNAs (bottom panel). Loading controls are provided in
Supplementary Figure S5B. The various RNA species are indicated by arrows.
Processed variants are denoted by asterisks.
enhancing effect could not be observed for the 1glmY and
1glmZ mutant strains. In this case, constant inhibition zones
were observed, regardless of the co-applied GlcN6SO4 potency,
indicating that GlcN6SO4 requires the small RNAs to act
(Supplementary Figure S7). To provide further evidence, we
tested the combined effect of Nva-FMDP and GlcN6SO4 in liquid
culture using the broth microdilution method. Serial dilutions
of a solution containing 250 µg/ml Nva-FMDP and 2.5 mg/ml
GlcN6SO4 were prepared in LB medium and subsequently
FIGURE 7 | Co-administration of GlcN6SO4 increases susceptibility of
wild-type E. coli towards Nva-FMDP. (A) Disk diffusion assay to address
the combined effect of Nva-FMDP and GlcN6SO4 on E. coli. Filter disks
containing 50 µg Nva-FMDP and various GlcN6SO4 amounts as indicated
were applied to MacConkey lactose plates that were seeded with E. coli
wild-type strain Z854. An exemplary experiment is shown at the top.
A diagram depicting the results of three independent experiments is shown
below. (B) Effect of GlcN6SO4 on susceptibility of E. coli to Nva-FMDP in LB
liquid medium. Serial dilutions of Nva-FMDP or GlcN6SO4 or a mixture of both
compounds were prepared in LB medium and subsequently inoculated with
5 × 105 CFU/ml of E. coli strain Z854. Cell densities were recorded following
12 h incubation.
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inoculated with the E. coli wild-type strain Z854. As controls,
serial dilutions containing only Nva-FMDP or GlcN6SO4 were
tested in parallel. Indeed, following 12 h incubation, the cultures
treated with the combination of both compounds showed a
slightly stronger growth defect as compared to the cultures
treated with Nva-FMDP alone (Figure 7B). Albeit weak, this
difference was detectable in each individual experiment. The
cultures that were solely supplemented with GlcN6SO4 exhibited
no growth impairment confirming that this GlcN6P analog is
nontoxic for the bacteria. Taken together, these results suggest
that a GlcN6P analog such as GlcN6SO4 may have the potential to
increase the antimicrobial activity of antibiotics targeting GlmS.
DISCUSSION
Peptide antibiotics targeting enzyme GlmS at the heart of
bacterial cell envelope synthesis, are known for a long time.
Structurally related oligopeptides such as Nva-FMDP have been
developed, which lack the toxic effects exhibited by bacilysin
on eukaryotic cells (Bontemps-Gracz et al., 1991). However,
although readily taken up by peptide transporters, Gram-negative
bacteria, such as E. coli, possess high intrinsic resistance towards
these drugs, limiting their potential clinical use. Here, we reveal
the mechanism underlying this intrinsic resistance. We show that
both E. coli as well as Salmonella respond to these antibiotics by
increased glmS expression, which compensates for inhibition of
GlmS enzymatic activity (Figures 2 and 6). Cells respond in a
dosage-dependent manner and adjust the level of glmS expression
exactly to the level required to overcome growth inhibition by the
GlmS inhibitor (Figure 5).
Responsible for this upregulation are two sRNAs which jointly
regulate the glmS mRNA. Inhibition of GlmS by antibiotics
leads to GlcN6P deprivation, which is sensed by sRNA GlmY
triggering its accumulation (Figures 2 and 4). As expected,
higher GlmY levels counteract degradation of sRNA GlmZ
consequently activating glmS expression by base-pairing. We
have recently shown that GlmY acts by sequestration of adapter
protein RapZ, which otherwise binds GlmZ and recruits RNase
E to inactivate the latter sRNA (Göpel et al., 2013, 2016). As
these two sRNAs act hierarchically to control glmS expression,
inactivation of either of them results in the inability to respond
to GlcN6P deprivation and consequently increases susceptibility
to GlmS inhibitors significantly, i.e., up to eightfold for E. coli
and up to 64-fold for Salmonella depending on the growth
medium (Tables 2 and 3). The basis for the different impact
of the sRNAs on drug susceptibility in these two species is
unknown, but could be caused by differences in basal glmS
expression levels remaining in the absence of GlmY or GlmZ. The
reason for the strong variation of efficacy of Nva-FMDP by the
growth medium also remains unclear. A reasonable explanation
might be provided by competition of Nva-FMDP with externally
available peptides for uptake (Marshall et al., 2003) and/or by
the known repression of the dipeptide transporter component
DppA by amino acids (Olson et al., 1991). Regardless of the
growth medium, GlmY/GlmZ endow both species with intrinsic
resistance against GlmS inhibitors. Thus, this mechanism might
be conserved in all species possessing GlmY/GlmZ, i.e., in
Enterobacteriaceae.
Our data indicate that suppression of the GlmY/GlmZ
circuit would substantially increase susceptibility of wild-type
bacteria to GlmS inhibitors. As the GlmY/GlmZ cascade is
sensing and responding to GlcN6P, a non-metabolizable analog
should accomplish this task. Initial experiments using GlcN6SO4
support this possibility as this compound increases efficacy
of Nva-FMDP in a GlmY/GlmZ-dependent manner, albeit
weakly (Figure 7; Supplementary Figure S7). The reason for
the weak activity of GlcN6SO4 is unclear, but hydrolysis by
so far unknown sulfatases or inefficient uptake is a likely
explanation. Thus, a future task will be the identification
of a stable GlcN6P analog that suppresses the GlmY/GlmZ
system efficiently. Testing the numerous artificial GlcN6P
mimics that have been synthesized to serve as artificial
actuators of the Gram-positive glmS ribozyme (Fei et al.,
2014), might provide a good starting point. Finally, it might
also be possible to design this analog on a rational basis,
once the GlcN6P sensor and the way how it interacts with
the amino sugar has been identified. As it sits at the top
of the regulatory cascade, sRNA GlmY is the most likely
candidate, a possibility that is currently addressed in our
laboratory.
The contribution of RNA regulatory elements to antibiotic
resistance and their potential value as drug targets is appreciated
only recently. Traditionally, screens for novel antimicrobial
targets or factors mediating drug resistance have focused
on proteins (Martinez and Rojo, 2011; Cox and Wright,
2013). A first systematic screen investigating the roles of
various Hfq-dependent sRNAs for susceptibility to different
classes of antibiotics has been reported recently (Kim
et al., 2015). Several sRNAs were shown to alter antibiotic
susceptibility in E. coli and Salmonella when deleted and/or
overproduced. The underlying mechanisms remain largely
unknown, but in two cases regulation of eﬄux pump
components by sRNAs might be involved (Nishino et al.,
2011; Kim et al., 2015; Parker and Gottesman, 2016). In
sum, there is increasing evidence that sRNAs have crucial
roles in genetic networks that provide intrinsic resistance to
antibiotics, either by acting via more unspecific mechanisms
(e.g., drug eﬄux pumps) and involving multiple targets
(Schnorpfeil et al., 2013; Kim et al., 2015) or by impacting
specifically on a single gene whose product is selectively
targeted by a cognate antibiotic (this study). It remains
to be investigated, whether sRNAs and other regulatory
RNA elements indeed represent druggable targets proving
useful for antimicrobial chemotherapy. In this regard, a
recent study is encouraging that identified a compound,
which binds to an RNA riboswitch and thereby suppresses
synthesis of the essential vitamin riboflavin (Howe et al.,
2015). Future work must determine whether the same holds
true for the GlmY/GlmZ system, i.e., whether a compound
could be identified that interferes with the sRNAs and
inhibits their response to GlcN6P deprivation, thereby
increasing susceptibility to GlmS inhibitors in combined
therapy.
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